Trial
NCT04605159
A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Respiratory Syncytial Virus Infections
Intervention
RSV MAT
Why stopped
Following a recommendation from the Independent Data Monitoring Committee of NCT04605159 (RSV MAT 009), GSK made the decision to stop enrolment and vaccination in the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-20